/ /

Advances

The oral pipeline for psoriasisOral options in the pipeline for psoriasis show promise.
Studies you may have missedOne expert summarizes science outside of dermatology that offers insight into the genetic toll of sun damage, the potential skin-protecting effects of vitamin B3, the sun-exposure threat posed by automobile side windows and more.
Combination therapy shows promising phase 2 resultsData suggest photodynamic therapy with the investigational topical methyl aminolevulinate may be an effective treatment for patients with severe facial acne.
FDA approves drug for pregnant women with HIVFDA recently approved an expansion to the prescribing information for darunavir (Prezista, Janssen Therapeutics), to treat pregnant women with HIV.
Ixekizumab effective psoriasis treatment through 60 weeksResults from three phase 3 trials, suggest ixekizumab (Talz, Eli Lilly & Company) is effective through 60 weeks of treatment among patients with moderate-to-severe plaque psoriasis.
New Products: FDA approves combination regimen to treat advanced RCCOther products discussed in this roundup include a smart-mobile connected ultrasound device, treatments for RCC, and more.
App aims to supplement physician visits for acneThe acne app offers a free and immediate analysis of acne type and severity; develops an individualized acne control plan; and monitors users’ progress. It aims to help consumers diagnose, treat, manage and prevent acne.
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Lessons from the past
Lessons from the pastScientists are digging into the past in search of genetic insight into modern skin diseases. Here are some of the hottest topics in the study of human history and skin disease.
FDA approves first once-monthly injection to lower cholesterolFDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August.

Poll

View Results